Puma Biotechnology (PBYI) Earnings Date, Estimates & Call Transcripts → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free pbyi Stock Alerts $4.99 +0.11 (+2.25%) (As of 02:25 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 2After Market ClosesConfirmedActual EPS (Feb. 29) $0.26 Missed By -$0.07 Consensus EPS (Feb. 29) $0.33 Get Puma Biotechnology Earnings AlertsEnter your email address below to receive the latest news and earnings results for PBYI and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenuePBYI Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PBYI Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. Puma Biotechnology Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany GuidanceQ1 20241($0.22)($0.22)($0.22) Q2 20241$0.13$0.13$0.13 Q3 20241$0.09$0.09$0.09 Q4 20241$0.24$0.24$0.24 FY 20244$0.24$0.24$0.24 Q1 20251$0.01$0.01$0.01 Q2 20251$0.09$0.09$0.09 Q3 20251$0.08$0.08$0.08 Q4 20251$0.08$0.08$0.08 FY 20254$0.26$0.26$0.26 Q1 20261$0.08$0.08$0.08 PBYI Earnings Date and InformationPuma Biotechnology last issued its quarterly earnings data on February 29th, 2024. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.07. The firm had revenue of $72.20 million for the quarter, compared to analysts' expectations of $73.22 million. Puma Biotechnology has generated $0.46 earnings per share over the last year ($0.46 diluted earnings per share) and currently has a price-to-earnings ratio of 10.8. Earnings for Puma Biotechnology are expected to remain at $0.29 per share in the coming year. Puma Biotechnology has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Puma Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call.. Read More Puma Biotechnology Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Confirmed)------- 2/29/2024Q4 2023$0.33$0.26($0.07)$0.26$73.22 million$72.20 million11/2/2023Q3 2023$0.08$0.12+$0.04$0.12$57.30 million$56.10 million8/3/2023Q2 2023$0.02$0.05+$0.03$0.05$51.37 million$54.60 million5/4/2023Q1 2023($0.10)$0.03+$0.13$0.03$49.71 million$52.80 million3/2/2023Q4 2022$0.06($0.12)($0.18)($0.12)$57.10 million$65.70 million11/3/2022Q3 2022($0.11)($0.01)+$0.10($0.01)$51.40 million$57.10 million Get the Latest News and Ratings for PBYI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Puma Biotechnology and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022$0.02$0.21+$0.19$0.21$53.20 million$59.50 million5/5/2022Q1 2022($0.13)($0.08)+$0.05($0.08)$45.07 million$45.70 million 3/3/2022Q4 2021($0.11)$0.10+$0.21$0.10$47.17 million$55.40 million 11/4/2021Q3 2021($0.31)($1.09)($0.78)($1.09)$53.44 million$46.20 million 8/5/2021Q2 2021($0.31)($0.13)+$0.18($0.13)$51.01 million$53.40 million 5/6/2021Q1 2021$0.29$0.40+$0.11$0.40$74.55 million$98.20 million Puma Biotechnology Earnings - Frequently Asked Questions When is Puma Biotechnology's earnings date? Puma Biotechnology has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on PBYI's earnings history. Did Puma Biotechnology beat their earnings estimates last quarter? In the previous quarter, Puma Biotechnology (NASDAQ:PBYI) missed the analysts' consensus estimate of $0.33 by $0.07 with a reported earnings per share (EPS) of $0.26. Learn more on analysts' earnings estimate vs. PBYI's actual earnings. How much revenue does Puma Biotechnology generate each year? Puma Biotechnology (NASDAQ:PBYI) has a recorded annual revenue of $235.60 million. How much profit does Puma Biotechnology generate each year? Puma Biotechnology (NASDAQ:PBYI) has a recorded net income of $21.59 million. PBYI has generated $0.46 earnings per share over the last four quarters. What is Puma Biotechnology's price-to-earnings ratio? Puma Biotechnology (NASDAQ:PBYI) has a trailing price-to-earnings ratio of 10.85 and a forward price-to-earnings ratio of 17.21. The price/earnings-to-growth ratio is 2.75. What is Puma Biotechnology's EPS forecast for next year? Puma Biotechnology's earnings are expected to stay at $0.29 per share in the next year. More Earnings Resources from MarketBeat Related Companies: 2seventy bio Earnings Results AC Immune Earnings Results Werewolf Therapeutics Earnings Results Xeris Biopharma Earnings Results Foghorn Therapeutics Earnings Results Vanda Pharmaceuticals Earnings Results AEON Biopharma Earnings Results Aldeyra Therapeutics Earnings Results uniQure Earnings Results Ovid Therapeutics Earnings Results Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:PBYI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
